For the Inventor, By the Inventor

Enter assignee name

London, United Kingdom

Autolus Limited

USPTO Granted Patents = 53

CIPO Patents = 24

EPO Patents = 21

Trademarks = 6

Forward Citations = 64

Loading Chart...

Loading Chart...

48 inventors (with patents filed for the assignee):

Martin Pulé (50 out of 70 patents)

Shaun Cordoba (32 out of 37 patents)

Simon Thomas (27 out of 27 patents)

4. Shimobi Onuoha (26 out of 31 patents)

5. Matteo Righi (10 out of 10 patents)

6. James Sillibourne (9 out of 9 patents)

7. Mathieu Ferrari (7 out of 7 patents)

8. Paul Maciocia (6 out of 8 patents)

9. Biao Ma (5 out of 5 patents)

10. Wen Chean Lim (4 out of 4 patents)

11. Evangelia Kokalaki (3 out of 3 patents)

12. Leila Mekkaoui (3 out of 6 patents)

13. Ekaterini Kotsopoulou (3 out of 3 patents)

14. John Anderson (2 out of 3 patents)

15. Ram Jha (2 out of 2 patents)

Core Competencies:

Chimeric Antigen Receptor

CAR T-Cells

Transgenic T-Cell Receptor

Cytokine Receptor

Nucleic Acid Construct

Retroviral Vectors

Lentiviral Vectors

Cancer Treatment

T-Cell Modulation

CD19 Binding Domain

CD22 Binding Domain

Chimeric Protein

53 patents: Sort by Forward Citations

1. 12454578 - Cytolytic immune cell comprising BCMA- and CD19-specific chimeric antigen receptors (2025-10-28),

2. 12398194 - Cell lexpressing two chimeric antigen receptors (CARs) at the cell surface (2025-08-26),

3. 12325733 - Binding domain (2025-06-10),

4. 12304942 - Cell comprising a chimeric antigen receptor or a transgenic T-cell receptor and comprising a chimeric TNF receptor (2025-05-20),

5. 12269860 - Compositions and methods comprising engineered chimeric antigen receptor and modulator of CAR (2025-04-08),

6. 12241124 - Molecular assessment of TRBC usage (2025-03-04),

7. 12241068 - CD79-specific chimeric antigen receptor (2025-03-04),

8. 12234295 - Chimeric transmembrane protein comprising antibody dimerization domains and a type I cytokine receptor endodomain, encoding nucleic acids thereof and methods of use thereof (2025-02-25),

9. 12187769 - Cell (2025-01-07),

10. 12049510 - Chimeric antigen receptor (2024-07-30),

11. 11982673 - Methods (2024-05-14),

12. 11982672 - Methods (2024-05-14),

13. 11965173 - Plasmid system (2024-04-23),

14. 11963981 - Chimeric antigen receptor (2024-04-23),

15. 11959084 - Nucleic acid construct (2024-04-16),

Autolus Limited is a biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy treatments. With a commitment to transforming the lives of cancer patients, Autolus is pioneering the use of T-cell programming and engineering to create next-generation, precision cell therapies. Through its innovative approach, Autolus aims to develop therapies that have the potential to achieve durable remissions and improve the outcome for patients with a wide range of cancers.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 2 2025

53 Patents

#61 in London

#322 in United Kingdom

#12,924 in the World

London, United Kingdom

Autolus Limited

Forward Citations = 64

48 inventors:

Martin Pulé (50 out of 70 patents)

Shaun Cordoba (32 out of 37 patents)

Simon Thomas (27 out of 27 patents)

4. Shimobi Onuoha (26 out of 31 patents)

5. Matteo Righi (10 out of 10 patents)

Please report any incorrect information to support@idiyas.com

Loading…